Rocket Pharmaceuticals Announces Participation at Upcoming Conferences
Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, announces
participation at the following upcoming industry conferences:
- Evercore ISI HealthConX Conference
- Gaurav Shah, M.D., Chief Executive Officer and President, will participate in a fireside chat on
November 28, 2018, at 1:15 p.m. Eastern Time in Boston, MA
- Barclays Gene Editing & Gene Therapy Summit
- Dr. Shah will present on November 29, 2018, at 11:15 a.m. Eastern Time in New York, NY
- American Society of Hematology 2018 Annual Meeting
- Dr. Juan Bueren, Head of the Hematopoietic Innovative Therapies Division at CIEMAT in Spain and
program principal investigator of the Phase 1/2 trial of RP-L102, will present the abstract “Advances in the Gene Therapy of
Patients with Fanconi Anemia” in an oral session on December 3, 2018, at 6:30 p.m. Pacific Time in San Diego, CA. The
presentation will include long-term follow up data from the first four patients treated, as presented at the 2018 Annual
Congress of the European Society of Gene and Cell Therapy in October.
A live audio webcast of the Evercore ISI presentation will be available on the Investors section of the company’s website,
www.rocketpharma.com. A replay of the presentation will be archived on the Rocket website following the conference.
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”) is an emerging, clinical-stage biotechnology company focused on
developing first-in-class gene therapy treatment options for rare, devastating diseases. Rocket’s multi-platform development
approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms.
Rocket's lead clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic
disease that leads to bone marrow failure and potentially cancer. Preclinical studies of additional bone marrow-derived disorders
are ongoing and target Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile Malignant
Osteopetrosis (IMO). Rocket is also developing an AAV-based gene therapy program for an undisclosed rare pediatric disease. For
more information about Rocket, please visit
www.rocketpharma.com.
Claudine Prowse, Ph.D.
SVP, Corporate Strategy and IRO
Rocket Pharma, Inc.
The Empire State Building, Suite 7530
New York, NY 10118
cp@rocketpharma.com
www.rocketpharma.com
investors@rocketpharma.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20181101005623/en/